Article

Tubal sterilization trends in the United States

School of Medicine, University of Manchester, Manchester, Greater Manchester, United Kingdom.
Fertility and sterility (Impact Factor: 4.59). 06/2010; 94(1):1-6. DOI: 10.1016/j.fertnstert.2010.03.029
Source: PubMed

ABSTRACT To review the rate, setting, and demographic characteristics of tubal sterilization and its current trend within contraceptive practice in the United States.
Review of U.S. health care statistics, NCHS publications, English-language literature searched using MEDLINE and PubMed, and bibliographies of key references.
Total annual cases of tubal sterilization have declined from 687,000 in 1995 to 643,000 in 2006, despite a 4% population growth. Interval sterilizations decreased by 12%. Postpartum sterilizations remained stable and follow 8%-9% of all live births. Tubal sterilizations remain more common in black and Hispanic women; women with lower income, lower education, and higher parity; and among women living in the South. From 1981 to 1995, inpatient interval sterilizations fully migrated to ambulatory surgery care.
After two decades of stable rates, there is a recent decline in sterilization. Improved access to a wide range of highly effective reversible contraceptives gives women flexibility when deciding how to manage their reproductive ability.

0 Followers
 · 
83 Views
  • Annales d Endocrinologie 10/2006; 67(5):468-468. DOI:10.1016/S0003-4266(06)72825-6 · 0.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In 2009, the Adiana® System for Permanent Contraception was approved by the US Food and Drug Administration and became the second device on the market for hysteroscopic sterilization. This article outlines the basics of the Adiana procedure as it relates to the initial 12-month clinical experience following commercial launch. Safety, efficacy, and practical applications are explored to provide a better understanding of product performance characteristics in the first year of actual clinical use.
    Reviews in obstetrics and gynecology 01/2010; 3(4):156-62.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine characteristics of U.S. women that are associated with use of long-acting reversible contraception and changes in these characteristics between 2002 and 2006-2008. We analyzed data from two nationally representative samples of women aged 15-44 in the National Survey of Family Growth, including 7,643 women in 2002 and 7,356 women in 2006-2008. We conducted simple and multinomial logistic regression analyses to identify demographic and reproductive health characteristics associated with use of long-acting reversible contraception. Long-acting reversible contraception (intrauterine devices and subdermal implants) use among U.S. women using contraception increased from 2.4% in 2002 to 5.6% in 2006-2008. The largest increases in long-acting reversible contraception use during this time occurred among the youngest and oldest age groups, non-Hispanic white and non-Hispanic African American women, foreign-born women, and those in the highest income group. High prevalence of long-acting reversible contraception use in 2006-2008 was seen among women who had given birth once or twice (10%), foreign-born women (8.8%), and Hispanic women (8.4%). After adjusting for key demographic and reproductive health characteristics, in comparison with users of other contraceptive methods and with those not using contraception who were at risk for unintended pregnancy, foreign-born women and women who experienced coitarche before age 18 were approximately twice as likely to be using long-acting reversible contraception as women without those characteristics. A more diverse population of women used long-acting reversible contraception in 2006-2008 compared with 2002. However, there is likely more potential for increased uptake, especially among populations historically not considered to be candidates for these methods.
    Obstetrics and Gynecology 06/2011; 117(6):1349-57. DOI:10.1097/AOG.0b013e31821c47c9 · 4.37 Impact Factor
Show more